KOL

Eclipse Fi Raises $1.9 Million to Build the First Decentralized Web3 Launch Hub on Cosmos and Leading L2s

Retrieved on: 
Tuesday, December 26, 2023

Eclipse is unique from other launchpads in that it is looking to solve the cross-chain user experience and sustainability issues that plague most launchpads.

Key Points: 
  • Eclipse is unique from other launchpads in that it is looking to solve the cross-chain user experience and sustainability issues that plague most launchpads.
  • Eclipse Founder, Simon Chadwick, says, "We have spent nearly two years developing a token launch model that is sustainable and focuses first and foremost on community.
  • The token launch included listings on Astroport, the leading DEX on Cosmos, Neutron, Arbitrum on Camelot DEX, and Gate.io.
  • You can learn more about Eclipse on the company's official social media channels:

Evaxion Announces Business Update and Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, December 19, 2023

On December 18, 2023, Evaxion priced a bridge financing round, expected to raise aggregate proceeds of approximately $5.3 million.

Key Points: 
  • On December 18, 2023, Evaxion priced a bridge financing round, expected to raise aggregate proceeds of approximately $5.3 million.
  • Cash burn for 2024, excluding financing activities, is expected at the level of $14 million (with Q1 cash burn being significantly higher than other quarters in 2024)
    COPENHAGEN, Denmark, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today provided a business update and announced its third quarter 2023 financial results.
  • A key focus for the first months has been to refine the Evaxion strategy with a strong focus on execution and value realization.
  • Evaxion announces a groundbreaking precision vaccine concept for hematological malignancies at the 65th American Society of Hematology (ASH) Annual Meeting.

Codexis Announces Achievement of Gram-scale Synthesis with its ECO Synthesis™ Platform

Retrieved on: 
Wednesday, December 13, 2023

REDWOOD CITY, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has achieved gram-scale synthesis with its Enzyme-Catalyzed Oligonucleotide (ECO) Synthesis™ technology. This critical technical milestone demonstrates the preparative-scale manufacture of an oligonucleotide, composed of the modified nucleotide building blocks typically used in ribonucleic acid (RNA) therapeutics, under process-like conditions.

Key Points: 
  • REDWOOD CITY, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has achieved gram-scale synthesis with its Enzyme-Catalyzed Oligonucleotide (ECO) Synthesis™ technology.
  • Successful completion of this milestone enables Codexis engineers to initiate a comprehensive assessment of the purity profile for small interference RNA (siRNA) developed with ECO Synthesis™ technology.
  • “Our scientists have done outstanding work to bring us to this critical milestone for the development of our ECO Synthesis™ technology so rapidly.
  • These distinguished experts were joined by Codexis leadership and discussed the growth of RNAi therapeutics as a modality, the manufacturing landscape and the potential role for Codexis’ ECO Synthesis™ platform to enable commercial-scale production of RNAi therapeutics.

Nusano to Host December 19 Virtual KOL Event on Emerging Trends in Radiotherapeutics

Retrieved on: 
Tuesday, December 12, 2023

They will discuss emerging trends in the radiotherapeutics landscape, a market that is projected to have a $30 billion potential in the next five years, a prospect that is capturing the attention of investors and companies alike.

Key Points: 
  • They will discuss emerging trends in the radiotherapeutics landscape, a market that is projected to have a $30 billion potential in the next five years, a prospect that is capturing the attention of investors and companies alike.
  • The event will highlight the isotopes that are the next frontier in radiotherapeutics development, exploring alternatives to industry staples like Lutetium-177 and Actinium-225.
  • Additionally, the discussions will delve into supply chain complexities, the role of CDMOs in bringing radiotherapeutics to patients, and the optimal timing for commercial-scale product development.
  • Nusano’s production platform enables the creation of rare and hard-to-produce medical radioisotopes in quantities needed for commercial-stage diagnostics and therapeutics.

Codexis KOL Event Highlights Significant Need for an Enzymatic Route of Synthesis in RNAi Therapeutics Manufacturing

Retrieved on: 
Monday, December 11, 2023

KOL participants included John Maraganore, PhD, Founder and Former Chief Executive Officer of Alnylam Pharmaceuticals, and member of Codexis’ Strategic Advisory Board, and David Butler, PhD, Chief Technology Officer at Hongene Biotech Corporation.

Key Points: 
  • KOL participants included John Maraganore, PhD, Founder and Former Chief Executive Officer of Alnylam Pharmaceuticals, and member of Codexis’ Strategic Advisory Board, and David Butler, PhD, Chief Technology Officer at Hongene Biotech Corporation.
  • “As the RNAi therapeutics field matures, many programs are targeting prevalent disease indications, such as cardiovascular and Alzheimer’s disease.
  • While I am confident in the potential for RNAi therapeutics to transform the treatment paradigms for millions of impacted patients, today’s manufacturing practices rely on traditional chemical synthesis methods that may not accommodate a sharp increase in demand.
  • “We were honored to have Dr. Maraganore and Dr. Butler share their insights on the RNAi manufacturing landscape during last week’s event.

Nurix Therapeutics Presents Positive Clinical Data from Its Novel Bruton’s Tyrosine Kinase (BTK) Degrader Programs, NX-5948 and NX-2127, at the 65th American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Monday, December 11, 2023

SAN FRANCISCO, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today presented positive clinical data from its orally available degraders of BTK, NX-5948 and NX-2127, which are being evaluated in separate Phase 1a/1b clinical trials in patients with relapsed or refractory (r/r) B-cell malignancies, including CLL, mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), marginal zone lymphoma (MZL), follicular lymphoma (FL), primary CNS lymphoma (PCNS), and Waldenström’s macroglobulinemia (WM). These data were presented in two posters at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, which is being held in San Diego, California.

Key Points: 
  • These data were presented in two posters at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, which is being held in San Diego, California.
  • BTK degraders represent a novel next generation therapy for these patients,” said Alexey Danilov, M.D., Ph.D.
  • Professor and Co-Director, Toni Stephenson Lymphoma Center, City of Hope National Medical Center and an investigator on both studies.
  • “CLL patients whose disease progresses on or after treatment with BTK inhibitors, most often due to the development of resistance, have no effective treatment options.

TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual Meeting and Exposition

Retrieved on: 
Saturday, December 9, 2023

“We are excited to present initial clinical data in our heme program, with six patients in our treatment arms and four patients in our control arm.

Key Points: 
  • “We are excited to present initial clinical data in our heme program, with six patients in our treatment arms and four patients in our control arm.
  • In contrast, these indicators were not achieved in any of the four control-arm patients.
  • After establishing the recommended Phase 2 dose, we plan to open expansion cohorts at that dose to further characterize safety and evaluate translational and efficacy endpoints.
  • We have designed TSC-100 and TSC-101 to address this unmet need and increase the success rate of transplantation.

Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101

Retrieved on: 
Saturday, December 9, 2023

The data suggest that Galapagos’ CAR-T point-of-care manufacturing platform can deliver fresh product in a median vein-to-vein time of seven days.

Key Points: 
  • The data suggest that Galapagos’ CAR-T point-of-care manufacturing platform can deliver fresh product in a median vein-to-vein time of seven days.
  • To further build a robust data package, patient recruitment of the Phase 1 dose-finding part of ATALANTA-1 is ongoing.
  • The data suggest that Galapagos’ point-of-care platform can deliver fresh product in a median vein-to-vein time of seven days.
  • Seven-day Vein-to-Vein Point-of-Care Manufactured CD19 CAR T Cells (GLPG5201) in Relapsed/Refractory CLL/SLL including Richter’s Transformation: Results from the Phase 1 Euplagia-1 Trial

Galapagos to Host KOL Event on December 10, 2023, at 11:00 AM PST to discuss new data presented at ASH 2023

Retrieved on: 
Thursday, December 7, 2023

Mechelen, Belgium; 6 December 2023, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will host a Key Opinion Leader (KOL) event during the 65th ASH Annual Meeting & Exposition in San Diego, CA, on Sunday, December 10, 2023, from 11:00 am PST to 12:30 pm PST.

Key Points: 
  • Mechelen, Belgium; 6 December 2023, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will host a Key Opinion Leader (KOL) event during the 65th ASH Annual Meeting & Exposition in San Diego, CA, on Sunday, December 10, 2023, from 11:00 am PST to 12:30 pm PST.
  • The in-person event will be held at the San Diego Marriott Gaslamp Quarter in the Presidio Ballroom B/C.
  • To register as an in-person attendee, please click here .
  • Galapagos leadership, including Paul Stoffels1, MD, CEO and Chairman, will provide updates on:
    A live question and answer will follow the formal presentations.

BioAtla Presented Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event

Retrieved on: 
Tuesday, December 5, 2023

SAN DIEGO, Dec. 05, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, presented a poster and discussion entitled “Phase 2 Trial of Mecbotamab Vedotin (BA3011), a CAB-AXL-ADC, Alone or in Combination with Nivolumab in Patients with Non-Squamous NSCLC” at the IASLC Conference December 1–3 and at a virtual KOL Event held December 4, 2023.

Key Points: 
  • SAN DIEGO, Dec. 05, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, presented a poster and discussion entitled “Phase 2 Trial of Mecbotamab Vedotin (BA3011), a CAB-AXL-ADC, Alone or in Combination with Nivolumab in Patients with Non-Squamous NSCLC” at the IASLC Conference December 1–3 and at a virtual KOL Event held December 4, 2023.
  • “Patients with AXL-positive treatment-refractory NSCLC have an unusually poor prognosis, few treatment options, and we don’t typically see clinical benefit in these patients,” said Dr.
  • Gay, MD, PhD, Assistant Professor, Department of Thoracic-Head & Neck Medical Oncology at MD Anderson Cancer Center.
  • Furthermore, the meaningful antitumor activity among patients with AXL expression of only 1% supports the development of BA3011 in target agnostic populations.